Medical Science
| Open Access |
DOI: Assessment of Risk and Prevention of Chronic Kidney Disease in Patients with Comorbid Conditions
Kayumov Nodrbek Ulug`bekovich , PhD, Assistant, Department of Internal Medicine, Nephrology and Hemodialysis, Tashkent State Medical University, UzbekistanAbstract
The study included 126 patients with comorbid conditions and risk factors for chronic kidney disease. The mean age of the patients was 59.3 ± 8.7 years. Arterial hypertension was observed in 96 patients, diabetes mellitus in 62 patients, cardiovascular diseases in 54 patients, and obesity in 47 patients. A decrease in estimated glomerular filtration rate below 60 ml/min/1.73 m² was detected in 39 patients, while albuminuria was found in 58 patients. A high and very high risk of chronic kidney disease progression was identified in 51 patients.The proposed prevention algorithm included regular monitoring of eGFR, albuminuria, blood pressure, glycemic status, lipid profile, body mass index, lifestyle correction, and elimination of nephrotoxic risk factors. The results indicate that patients with arterial hypertension, diabetes mellitus, obesity, and cardiovascular diseases require systematic screening and multidisciplinary follow-up. The use of an integrated risk assessment algorithm may contribute to early detection of renal dysfunction and prevention of chronic kidney disease progression in patients with comorbid pathology.
Keywords
Chronic kidney disease, comorbid conditions, arterial hypertension
References
Kidney Disease: Improving Global Outcomes CKD Work Group. KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney International. 2024;105(4S)–S314.
Kidney Disease: Improving Global Outcomes Blood Pressure Work Group. KDIGO 2021 Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease. Kidney International. 2021;99(3S)–S87.
Kidney Disease: Improving Global Outcomes Diabetes Work Group. KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease. Kidney International. 2022;102(5S)–S127.
American Diabetes Association Professional Practice Committee for Diabetes. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes—2026. Diabetes Care. 2026;49(Suppl. 1)–S260.
De Boer I.H., Khunti K., Sadusky T., Tuttle K.R., Neumiller J.J., Rhee C.M., Rosas S.E., Rossing P., Bakris G. Diabetes Management in Chronic Kidney Disease: A Consensus Report by the American Diabetes Association and Kidney Disease: Improving Global Outcomes. Diabetes Care. 2022;45(12):3075–3090.
GBD Chronic Kidney Disease Collaboration. Global, regional, and national burden of chronic kidney disease, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. The Lancet. 2020;395(10225):709–733.
Heerspink H.J.L., Stefánsson B.V., Correa-Rotter R., Chertow G.M., Greene T., Hou F.F., Mann J.F.E., McMurray J.J.V., Lindberg M., Rossing P., et al. Dapagliflozin in Patients with Chronic Kidney Disease. The New England Journal of Medicine. 2020;383(15):1436–1446.
The EMPA-KIDNEY Collaborative Group. Empagliflozin in Patients with Chronic Kidney Disease. The New England Journal of Medicine. 2023;388(2):117–127.
Perkovic V., Jardine M.J., Neal B., Bompoint S., Heerspink H.J.L., Charytan D.M., Edwards R., Agarwal R., Bakris G., Bull S., et al. Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy. The New England Journal of Medicine. 2019;380(24):2295–2306.
Bakris G.L., Agarwal R., Anker S.D., Pitt B., Ruilope L.M., Rossing P., Kolkhof P., Nowack C., Schloemer P., Joseph A., et al. Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes. The New England Journal of Medicine. 2020;383(23):2219–2229.
Download and View Statistics
Copyright License
Copyright (c) 2026 Kayumov Nodrbek Ulug`bekovich
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors retain the copyright of their manuscripts, and all Open Access articles are disseminated under the terms of the Creative Commons Attribution License 4.0 (CC-BY), which licenses unrestricted use, distribution, and reproduction in any medium, provided that the original work is appropriately cited. The use of general descriptive names, trade names, trademarks, and so forth in this publication, even if not specifically identified, does not imply that these names are not protected by the relevant laws and regulations.